Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1399-0012|29|9|813-819

ISSN： 0902-0063

Source： CLINICAL TRANSPLANTATION (ELECTRONIC), Vol.29, Iss.9, 2015-09, pp. : 813-819

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sofosbuvir and ribavirin use in wait‐listed patients with hepatitis C should be selective

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 7-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin

By  

HEPATOLOGY, Vol. 61, Iss. 2, 2015-02 ,pp. : 471-480

John Wiley & Sons Inc

Access to resources Recommend Favorite

Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1047-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite